GO:0016311 dephosphorylation: Mechanism, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0016311 dephosphorylation is the biological process of removing one or more phosphoric (ester or anhydride) residues from a molecule, as defined by QuickGO.
• Dephosphorylation is catalyzed by protein phosphatases such as calcineurin (PP2B) and protein phosphatase 1 (PP1), which reverse kinase-mediated signaling [1,3,4,5,6].
• Key substrates include NFAT, AMPKα2, EGFR, shootin1, Six2, and FT, linking dephosphorylation to immunity, metabolism, cancer, neurodevelopment, and flowering [1,2,4,6,7,8].
• Dephosphorylation regulates protein stability, localization, and activity; for example, calcineurin-mediated dephosphorylation of EGFR at S1046/1047 enhances its stability.
• Dysregulated dephosphorylation contributes to cardiac hypertrophy, cancer, and neurological disorders, making phosphatases and their substrates attractive therapeutic targets [2,4,8].
• CRISPR-based knockout, point-mutation, knock-in, and overexpression models enable precise interrogation of dephosphorylation events in disease-relevant cell types [1,2,4,6,7,8].
Description
Dephosphorylation (GO:0016311) is a fundamental biological process that removes phosphate groups from proteins, lipids, and other molecules, thereby reversing the effects of protein kinases [1,4]. This process is essential for signal transduction, cellular homeostasis, and development, as it controls the activity, stability, and interactions of numerous key regulatory proteins [1,2,4,6,7,8]. Protein phosphatases such as calcineurin and protein phosphatase 1 (PP1) are the primary enzymes responsible for dephosphorylation, and their substrate specificity is often guided by interactor proteins or composite motifs [3,5]. Researchers study dephosphorylation to understand how cells dynamically regulate signaling networks in health and disease. For instance, calcineurin-mediated dephosphorylation of NFAT controls its stability and immune function, while dephosphorylation of AMPKα2 by PRL2 promotes cardiac hypertrophy. In the nervous system, PP1-dependent dephosphorylation of shootin1 is required for netrin-1-induced axon guidance, and dephosphorylation of Six2 protects dopaminergic neurons. In plants, dephosphorylation of FT mediates flowering time. These examples highlight the broad biological and clinical importance of dephosphorylation. Given its central role, dephosphorylation is a major focus in biomedical research, with implications for cancer, cardiovascular disease, and neurodegeneration [2,4,8]. Understanding the mechanisms, regulation, and disease relevance of dephosphorylation requires robust experimental models, including CRISPR-engineered cell lines and animal models [1,2,4,6,7,8].
dephosphorylation At A Glance
| GO ID | GO:0016311 |
|---|---|
| GO term | dephosphorylation |
| Ontology | biological_process |
| Synonym | none |
| Major function | Removal of phosphate groups from molecules, reversing kinase action and regulating protein activity, stability, and interactions [1,2,4,6,7,8]. |
| Key enzymes | Protein phosphatases such as calcineurin (PP2B) and protein phosphatase 1 (PP1) [1,3,4,5,6]. |
| Representative substrates | NFAT, AMPKα2, EGFR, shootin1, Six2, FT [1,2,4,6,7,8]. |
| Disease relevance | Cardiac hypertrophy, cancer, neurological disorders [2,4,8]. |
| Research methods | CRISPR knockout/knock-in, phospho-specific antibodies, mass spectrometry, biochemical assays [1,2,4,6,7,8]. |
What Is GO:0016311?
According to the Gene Ontology (QuickGO), dephosphorylation (GO:0016311) is defined as the process of removing one or more phosphoric (ester or anhydride) residues from a molecule. This includes the enzymatic removal of phosphate groups from proteins, lipids, and other biomolecules, typically catalyzed by phosphatases [1,3,4,5,6].
Why Is dephosphorylation Important in Cell Biology?
Dephosphorylation is a cornerstone of cellular regulation because it counteracts phosphorylation, thereby controlling the duration and intensity of signaling cascades [1,4]. It governs critical processes such as immune cell activation, cardiac growth, axon guidance, and flowering time [1,2,6,7]. Dysregulation of dephosphorylation is linked to diseases including cancer, cardiac hypertrophy, and neurodegeneration, making it a prime target for therapeutic intervention [2,4,8].
• Regulates protein stability: calcineurin-mediated dephosphorylation of EGFR at S1046/1047 enhances its stability.
• Controls immune responses: dephosphorylation of NFAT by calcineurin inhibits Skp2-mediated degradation.
• Modulates metabolism: PRL2 dephosphorylates AMPKα2 to promote cardiac hypertrophy.
• Guides neural wiring: PP1 dephosphorylates shootin1 to regulate netrin-1-induced axon guidance.
• Protects neurons: dephosphorylation of Six2Y129 protects tyrosine hydroxylase-positive cells in the SNpc.
• Regulates plant development: dephosphorylation-dependent molecular switch for FT repression mediates flowering in Arabidopsis.
• Involved in cancer: calcineurin and PP1 substrates are implicated in tumor progression [1,4].
• Target for cardiovascular disease: PRL2-AMPKα2 axis is a potential therapeutic target for hypertrophy.
• Provides mechanistic insights: interactor-guided dephosphorylation by PP1 reveals substrate specificity.
• Enables precision medicine: CRISPR models allow functional dissection of dephosphorylation events [1,2,4,6,7,8].
What Happens During dephosphorylation?
Recognition of Phosphorylated Substrates
In simple terms: The phosphatase enzyme finds and binds to its target protein that carries a phosphate group.
Dephosphorylation begins with the specific recognition of phosphorylated substrates by protein phosphatases. This specificity is often mediated by interactor proteins or composite motifs; for example, a composite motif in calcimembrin/C16orf74 dictates multimeric dephosphorylation by calcineurin. Similarly, interactor-guided dephosphorylation by protein phosphatase-1 ensures targeting to specific substrates. This step is crucial for ensuring that only the correct proteins are dephosphorylated at the right time and place [3,5].
Catalytic Removal of Phosphate Groups
In simple terms: The phosphatase enzyme chemically removes the phosphate group from the target protein.
Once bound, the phosphatase catalyzes the hydrolysis of the phosphoester bond, releasing inorganic phosphate and the dephosphorylated protein. Calcineurin, a calcium/calmodulin-dependent phosphatase, dephosphorylates NFAT, thereby inhibiting its Skp2-mediated degradation. Calcineurin also dephosphorylates EGFR at serine 1046/1047, enhancing its stability. PRL2 directly dephosphorylates AMPKα2 to promote cardiac hypertrophy. These examples illustrate the diverse substrates and functional outcomes of the catalytic step [1,2,4].
Conformational and Functional Consequences
In simple terms: After the phosphate is removed, the target protein changes shape or activity, leading to downstream effects.
Dephosphorylation often induces conformational changes that alter protein function, localization, or interactions. For instance, dephosphorylation of shootin1 by PP1 regulates netrin-1-induced axon guidance, likely by modulating its interaction with other cytoskeletal proteins. In Arabidopsis, a dephosphorylation-dependent molecular switch represses FT, thereby mediating flowering time. Dephosphorylation of Six2Y129 protects tyrosine hydroxylase-positive cells in the SNpc by regulating TEA domain 1 expression. These downstream effects are critical for cellular responses [6,7,8].
Regulation of Dephosphorylation
In simple terms: The activity of phosphatases is tightly controlled by various signals and interactors.
Dephosphorylation is regulated at multiple levels, including calcium signaling for calcineurin [1,3,4], and interactor proteins for PP1. For example, calcineurin activity is calcium-dependent, linking dephosphorylation to intracellular calcium signals [1,4]. The composite motif in calcimembrin/C16orf74 modulates calcineurin substrate specificity. Additionally, phosphatases can be regulated by phosphorylation themselves, creating feedback loops. This regulation ensures precise spatial and temporal control of dephosphorylation [1,3,4,5].
Key Genes Involved in GO:0016311 dephosphorylation
The following genes and proteins are central to dephosphorylation processes, as supported by recent literature.
| Gene | Major Role | Research Relevance |
|---|---|---|
| PPP3CA (Calcineurin A) | Catalytic subunit of calcineurin; dephosphorylates NFAT, EGFR | Immune regulation, cancer, cardiac hypertrophy [1,3,4] |
| PPP3R1 (Calcineurin B) | Regulatory subunit of calcineurin; calcium sensing | Calcineurin activation in signaling [1,3,4] |
| PPP1CA (PP1α) | Catalytic subunit of protein phosphatase 1; dephosphorylates shootin1 | Axon guidance, neuronal development [5,6] |
| PPP1R1A (DARPP-32) | Inhibitor of PP1; regulates phosphatase activity | Neuronal signaling, drug addiction |
| NFAT (NFATC1-4) | Transcription factors dephosphorylated by calcineurin | Immune response, cancer |
| PRKAA2 (AMPKα2) | Energy sensor; dephosphorylated by PRL2 | Cardiac hypertrophy, metabolism |
| EGFR | Receptor tyrosine kinase; dephosphorylated at S1046/1047 by calcineurin | Cancer, cell proliferation |
| SHOOTIN1 | Neural wiring protein; dephosphorylated by PP1 | Axon guidance, neurodevelopment |
| SIX2 | Transcription factor; dephosphorylated at Y129 | Neuroprotection, Parkinson's disease |
| FT (FLOWERING LOCUS T) | Florigen; regulated by dephosphorylation | Plant flowering time |
| C16orf74 (calcimembrin) | Composite motif protein; guides calcineurin dephosphorylation | Substrate specificity |
| PTPN11 (SHP2) | Protein tyrosine phosphatase | Cancer, Noonan syndrome |
| PTEN | Lipid phosphatase; dephosphorylates PIP3 | Cancer, tumor suppression |
| CDC25 | Dual-specificity phosphatase; regulates cell cycle | Cancer, cell cycle |
| DUSP1 (MKP-1) | MAP kinase phosphatase | Inflammation, cancer |
| PP2A | Serine/threonine phosphatase | Multiple signaling pathways |
| PPM1A | Protein phosphatase 1A | Stress response, cancer |
| MTM1 | Myotubularin; lipid phosphatase | Myotubular myopathy |
How Is dephosphorylation Regulated?
Dephosphorylation is regulated by calcium signaling (for calcineurin) [1,3,4], interactor proteins (for PP1), and post-translational modifications of phosphatases themselves. For example, calcineurin is activated by calcium/calmodulin, which triggers dephosphorylation of NFAT and EGFR [1,4]. The composite motif in calcimembrin/C16orf74 modulates calcineurin substrate specificity. PP1 activity is guided by regulatory subunits and interactors. Additionally, phosphatases can be inhibited by phosphorylation, creating feedback loops.
dephosphorylation and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| PPP3CA | Cancer, cardiac hypertrophy | Knockout and point-mutation cell lines [1,3,4] |
| PRKAA2 | Cardiac hypertrophy | Overexpression and knockout models |
| EGFR | Cancer | Point mutation at S1046/1047 |
| SHOOTIN1 | Neurodevelopmental disorders | Knockout and phospho-mutant knock-in |
| SIX2 | Parkinson's disease | Y129 point mutation knock-in |
Dephosphorylation in Cancer
Dephosphorylation regulates key oncogenic and tumor suppressor pathways. Calcineurin-mediated dephosphorylation of NFAT inhibits its Skp2-mediated degradation, potentially affecting immune evasion and tumor progression. Dephosphorylation of EGFR at S1046/1047 by calcineurin enhances its stability, which could promote cancer cell proliferation. Protein phosphatase 1 (PP1) and its regulators are also implicated in cell cycle control and cancer.
Dephosphorylation in Cardiovascular Disease
PRL2 directly dephosphorylates AMPKα2 to promote cardiac hypertrophy, highlighting a role for dephosphorylation in heart disease. This pathway represents a potential therapeutic target for hypertrophy and heart failure.
Dephosphorylation in Neurological Disorders
Dephosphorylation of shootin1 by PP1 regulates netrin-1-induced axon guidance, which is critical for neural development. Dephosphorylation of Six2Y129 protects tyrosine hydroxylase-positive cells in the SNpc, suggesting a protective role in Parkinson's disease. Dysregulation of these processes may contribute to neurodevelopmental and neurodegenerative disorders [6,8].
From dephosphorylation-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does calcineurin-mediated dephosphorylation of NFAT affect its stability? | PPP3CA knockout and NFAT phospho-mutant knock-in |
| Does PRL2 dephosphorylation of AMPKα2 promote cardiac hypertrophy? | PRL2 overexpression and AMPKα2 phospho-mutant knock-in |
| Does EGFR S1046/1047 dephosphorylation enhance stability? | EGFR S1046A/S1047A point mutation |
| Does PP1 dephosphorylation of shootin1 regulate axon guidance? | SHOOTIN1 phospho-mutant knock-in and PP1 knockout |
| Does Six2Y129 dephosphorylation protect dopaminergic neurons? | SIX2 Y129F knock-in and knockout |
| Does dephosphorylation of FT mediate flowering time? | FT phospho-mutant knock-in in Arabidopsis |
How to Study the dephosphorylation Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Phospho-specific Western blot | Levels of specific phosphorylated proteins | Validation of dephosphorylation events [1,2,4,6,7,8] |
| Mass spectrometry | Global phosphorylation/dephosphorylation sites | Discovery of novel substrates [3,5] |
| CRISPR-Cas9 knockout | Loss-of-function of phosphatase or substrate | Causal role in dephosphorylation [1,2,4,6,7,8] |
| CRISPR point mutation | Effect of specific phospho-site mutation | Mechanistic dissection [4,8] |
| CRISPR knock-in | Tagged or mutant protein expression | Localization and interaction studies [6,7] |
| Overexpression | Gain-of-function of phosphatase or substrate | Disease modeling |
| In vitro phosphatase assay | Enzymatic activity of phosphatases | Inhibitor screening [1,3,4] |
| Proximity ligation assay | Protein-protein interactions | Interactor-guided dephosphorylation |
Phospho-specific Antibodies and Western Blotting
Phospho-specific antibodies are widely used to detect changes in phosphorylation levels of specific proteins. For example, dephosphorylation of EGFR at S1046/1047 was demonstrated using phospho-specific antibodies. This method is cost-effective and suitable for validating dephosphorylation events in cell lysates [1,2,4,6,7,8].
Mass Spectrometry-Based Phosphoproteomics
Mass spectrometry enables global profiling of phosphorylation and dephosphorylation events. It can identify novel substrates and sites, such as those regulated by calcineurin or PP1 [3,5]. This approach is powerful for discovering dephosphorylation networks but requires specialized equipment and bioinformatics [3,5].
CRISPR-Cas9 Genome Editing
CRISPR-Cas9 allows precise knockout, point mutation, knock-in, and overexpression of genes involved in dephosphorylation. For instance, knockout of PPP3CA or point mutation of EGFR S1046/1047 can reveal functional consequences [1,2,4,6,7,8]. This method is essential for causal inference in dephosphorylation research [1,2,4,6,7,8].
In Vitro Phosphatase Assays
Recombinant phosphatases and substrates can be used to measure dephosphorylation activity in vitro. For example, calcineurin activity towards NFAT or EGFR peptides can be quantified [1,3,4]. These assays are useful for mechanistic studies and inhibitor screening [1,3,4].
How CRISPR Can Be Used to Study GO:0016311 dephosphorylation
Knockout
CRISPR knockout of phosphatase genes such as PPP3CA or PPP1CA can abolish dephosphorylation of specific substrates, revealing their functional importance. For example, PPP3CA knockout prevents NFAT dephosphorylation and alters its stability. Knockout of PRL2 would block AMPKα2 dephosphorylation and hypertrophy.
Point Mutation
Point mutations at phospho-acceptor sites (e.g., EGFR S1046A/S1047A, SIX2 Y129F) can prevent dephosphorylation, mimicking a constitutively phosphorylated state. These models are invaluable for dissecting the precise role of individual phosphorylation sites [4,8].
Knock-in
Knock-in of tagged or mutant proteins (e.g., GFP-tagged shootin1, FT phospho-mutant) allows real-time tracking of dephosphorylation dynamics and interaction partners. This approach is ideal for studying localization and complex formation [6,7].
Overexpression
Overexpression of phosphatases (e.g., PRL2) or substrates can model gain-of-function states relevant to disease, such as cardiac hypertrophy. It can also be used to amplify dephosphorylation signals for biochemical assays.
How EDITGENE Supports dephosphorylation Research
Researchers studying dephosphorylation-related genes often need to determine whether a candidate gene is causally involved in a specific biological process or disease. This requires precise genetic models that can knockout, mutate, tag, or overexpress the gene of interest in relevant cell types. EDITGENE provides a comprehensive suite of CRISPR services to accelerate such discoveries.
Contact EDITGENE today to design your custom CRISPR model for dephosphorylation research.
Frequently Asked Questions About dephosphorylation
What is dephosphorylation GO:0016311?
Dephosphorylation (GO:0016311) is the biological process of removing one or more phosphoric (ester or anhydride) residues from a molecule, as defined by QuickGO. It is catalyzed by phosphatases and reverses kinase action [1,4].
What genes are involved in dephosphorylation?
Key genes include PPP3CA (calcineurin), PPP1CA (PP1), PRKAA2 (AMPKα2), EGFR, SHOOTIN1, SIX2, and FT, among others [1,2,4,6,7,8].
How does calcineurin mediate dephosphorylation?
Calcineurin is a calcium/calmodulin-dependent phosphatase that dephosphorylates substrates such as NFAT and EGFR, thereby regulating their stability and function [1,3,4].
What is the role of dephosphorylation in cancer?
Dephosphorylation can enhance EGFR stability and inhibit NFAT degradation, potentially promoting tumor progression [1,4]. Phosphatases like PTEN and CDC25 are also critical in cancer [4,5].
How is dephosphorylation studied experimentally?
Common methods include phospho-specific Western blotting, mass spectrometry, in vitro phosphatase assays, and CRISPR-Cas9 genome editing [1,2,3,4,5,6,7,8].
What diseases are linked to dephosphorylation?
Dephosphorylation is implicated in cardiac hypertrophy, cancer, Parkinson's disease, and neurodevelopmental disorders [2,4,6,8].
What is the difference between phosphorylation and dephosphorylation?
Phosphorylation adds a phosphate group via kinases, while dephosphorylation removes it via phosphatases. Together they regulate protein activity and signaling [1,4].
Can CRISPR be used to study dephosphorylation?
Yes, CRISPR knockout, point mutation, knock-in, and overexpression models enable precise interrogation of dephosphorylation events in cells and animals [1,2,4,6,7,8].
What are the major phosphatases in dephosphorylation?
Major phosphatases include calcineurin (PP2B), protein phosphatase 1 (PP1), PP2A, and PRL2, each with specific substrates and regulatory mechanisms [1,2,3,4,5,6].
How does dephosphorylation regulate protein stability?
Dephosphorylation can alter protein stability by affecting ubiquitination and degradation; for example, calcineurin-mediated dephosphorylation of EGFR enhances its stability.
Conclusion
Dephosphorylation (GO:0016311) is a central biological process that reverses phosphorylation to control protein function, stability, and signaling. Its dysregulation contributes to cancer, cardiovascular disease, and neurological disorders, making it a key area of biomedical research [1,2,4,6,7,8]. Advances in CRISPR genome editing and phosphoproteomics are accelerating the discovery of dephosphorylation mechanisms and therapeutic targets [1,2,3,4,5,6,7,8]. EDITGENE provides comprehensive CRISPR services, including knockout, point mutation, knock-in, overexpression, library screening, and bioinformatics, to support researchers in dissecting dephosphorylation pathways and developing new treatments.
References
- 1. Hanaki S et al.. 2024. Dephosphorylation of NFAT by Calcineurin inhibits Skp2-mediated degradation.. J Biochem 175(3):235-244 PMID: 38030387
- 2. Han X et al.. 2025. Cardiomyocyte PRL2 Promotes Cardiac Hypertrophy via Directly Dephosphorylating AMPKα2.. Circ Res 136(7):645-663 PMID: 39950300
- 3. Bradburn DA et al.. 2025. A composite motif in calcimembrin/C16orf74 dictates multimeric dephosphorylation by calcineurin.. Nat Commun 16(1):9941 PMID: 41224739
- 4. Masaki T et al.. 2023. Dephosphorylation of the EGFR protein by calcineurin at serine 1046/1047 enhances its stability.. Biochem Biophys Res Commun 641:84-92 PMID: 36525928
- 5. Boens S et al.. 2013. Interactor-guided dephosphorylation by protein phosphatase-1.. Methods Mol Biol 1053:271-81 PMID: 23860659
- 6. Kastian RF et al.. 2023. Dephosphorylation of neural wiring protein shootin1 by PP1 phosphatase regulates netrin-1-induced axon guidance.. J Biol Chem 299(5):104687 PMID: 37044214
- 7. Zhang Y et al.. 2024. A dephosphorylation-dependent molecular switch for FT repression mediates flowering in Arabidopsis.. Plant Commun 5(3):100779 PMID: 38115582
- 8. Zhang CT et al.. 2023. Dephosphorylation of Six2Y129 protects tyrosine hydroxylase-positive cells in SNpc by regulating TEA domain 1 expression.. iScience 26(7):107049 PMID: 37534182
